drugset / Trial / NCT04381832
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of etrumadenant (AB928)-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).
Timeline
- Start
- 2020-07-07
- Primary completion
- 2024-08-30
- Completion
- 2024-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | — | Intravenous |
| Subject | Enzalutamide | Other / unclassified | — | Oral |
| Subject | Etrumadenant | Small molecule | — | Oral |
| Subject | Quemliclustat | Small molecule | — | Intravenous |
| Subject | Sacituzumab Govitecan | Monoclonal antibody | — | Intravenous |
| Subject | Zimberelimab | Monoclonal antibody | — | Intravenous |